In a study to be presented today at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting ™, in Dallas, Texas, researchers will report findings that indicate that preterm birth interventions should be tailored for underlying risk factors and pathways.

A nationwide, federally funded study has found that testing a developing fetus' DNA through chromosomal microarray (CMA) provides more information about potential disorders than does the standard method of prenatal testing, which is to visually examine the chromosomes (karyotyping).

KENNESAW, Ga., Dec. 5, 2011 /PRNewswire/ -- MiMedx Group, Inc.

KENNESAW, Ga., Oct. 20, 2011 /PRNewswire/ -- MiMedx Group, Inc.

A new DNA-based prenatal blood test that can strikingly reduce the number of risky diagnostic procedures needed to identify a pregnancy with Down syndrome is ready to be introduced into clinical practice.